A study on quality of Paridis Rhizoma and consideration on standards of Paridis Rhizoma in Chinese Pharmacopoeia.
10.19540/j.cnki.cjcmm.20200110.201
- Author:
Tian-Ying JIA
1
;
Xiao-Nan ZHANG
2
;
Tai SU
2
;
Xiao-Yan YANG
2
;
Hai-Li WANG
1
;
Jie-Ping XIN
1
;
Meng-Nan LIU
1
;
Jing-Kun WANG
2
;
Xiang-Ri LI
1
Author Information
1. School of Chinese Pharmacy, Beijing University of Chinese Medicine Beijing 102488, China.
2. Yunnan Baiyao Group Limited Ltd. Kunming 650500, China.
- Publication Type:Journal Article
- Keywords:
Chinese Pharmacopoeia;
Paridis Rhizoma;
quality research
- MeSH:
Chromatography, High Pressure Liquid;
Drugs, Chinese Herbal;
Rhizome;
Saponins;
Trillium
- From:
China Journal of Chinese Materia Medica
2020;45(10):2425-2430
- CountryChina
- Language:Chinese
-
Abstract:
Thin layer chromatography, high performance liquid chromatography and multivariate statistical analysis were integrated in current study to provide a basis for the quality evaluation and the standard improvement of Paridis Rhizoma(Chinese name: Chong-lou). The results demonstrated that the primary saponins in the two authorized sources of Paridis Rhizoma were polyphyllinsⅠ, Ⅱ and Ⅶ, while the rhizome of Trillium tschonoskii an adulterant of Paridis Rhizoma was rich of polyphyllin Ⅵ. Therefore, the apparent content of polyphyllin Ⅵ plays a determinant role towards the source authentication of raw materials and decoction slices of Paridis Rhizoma, whose adulterants frequently occur in the market. Moreover, the contents of polyphyllin Ⅵ in the two authorized sources could meet the requirements of Chinese Pharmacopoeia. Therefore, we suggested that polyphyllin Ⅵ should not be omitted from the quality standard of Paridis Rhizoma in the Chinese Pharmacopoeia, and on the other side, polyphyllinsⅠ, Ⅱ and Ⅶ should be the eligible quality indicators. The study aims to sound information and evidences for the quality evaluation of Paridis Rhizoma, and also to provide a theoretical basis for the standard revision of Paridis Rhizoma in the future Chinese Pharmacopoeia.